Skip to main content

Table 3 Clinical characteristics of patients with and without MACCE in female PCI group

From: Improvement of long-term clinical outcomes by successful PCI in the very elderly women with ACS

Variables MACCE group (n = 56) Without MACCE group (n = 176) P value
Demographic
 Age (years) 83 (81, 84) 82 (81, 84) 0.188
 BMI (kg/m2) 24.3 (22.5, 26.5) 24.5 (22.3, 27.0) 0.461
Past medical history
 Hypertension, n (%) 45 (80.4) 140 (79.5) 0.895
 Diabetes mellitus, n (%) 18 (32.1) 74 (42.0) 0.187
 Dyslipidemia, n (%) 21 (37.5) 75 (42.6) 0.499
 Prior MI, n (%) 2 (3.6) 15 (8.5) 0.216
 Prior stroke, n (%) 13 (23.2) 43 (24.4) 0.853
 Smoking, n (%) 4 (7.1) 19 (10.8) 0.426
Clinical diagnosis
 UAP, n (%) 15 (26.8) 96 (54.5) < 0.001
 Non-STEMI, n (%) 16 (29.1) 39 (22.2) 0.326
 STEMI, n (%) 25 (44.6) 41 (23.3) 0.002
Length of stay (days) 8 (6, 10) 7 (6, 10) 0.513
Laboratory finding
 HbA1c (%) 6.2 (5.6, 6.9) 6.2 (5.7, 7.3) 0.308
 TC (mmol/L) 4.2 (3.6, 5.3) 4.4 (3.7, 5.1) 0.589
 LDL-C (mmol/L) 2.40 (1.88, 3.24) 2.49 (2.02, 2.94) 0.738
 TG (mmol/L) 1.3 (0.92, 1.84) 1.3 (0.98, 1.89) 0.555
 Creatinine (umol/L) 81.3 (71, 101.6) 74.2 (65.8, 89.1) 0.029
 ALT (U/L) 18 (10, 31) 14 (10, 20) 0.036
 CK-MB (ng/ml) 2.1 (1.1, 8.1) 1.7 (1.0, 3.7) 0.071
 Log NT-proBNP 3.23 (2.87, 3.71) 2.83 (2.47, 3.30) < 0.001
 LVEF ≥ 50%, n (%) 39 (72.2) 158 (91.9) < 0.001
TIMI bleeding, n (%)
 Major 7 (12.5) 8 (4.5) 0.035
 Non-major 6 (10.7) 30 (17) 0.254
Medication during follow up, n (%)
 Aspirin 40 (71.4) 149 (84.7) 0.026
 P2Y12 receptor antagonist* 45 (80.4) 170 (96.6) < 0.001
 β-blocker 24 (42.9) 116 (65.9) 0.002
 ACEI/ARB 23 (41.1) 89 (50.6) 0.215
 Statin 43 (76.8) 153 (86.9) 0.068
  1. *P2Y12 receptor antagonist within 12 months after PCI. P, level of statistical significance
  2. BMI body mass index, MI myocardial infarction, UAP unstable angina pectoris, NSTEMI non-ST-segment elevation myocardial infarction, STEMI ST-elevation myocardial infarction, HbA1c Hemoglobin A1c, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride, ALT alanine aminotransferase, CK-MB creatine kinase-MB, NT-proBNP N-Terminal pro-brain natriuretic peptide, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers